The prognostic value of peak oxygen uptake in obstructive hypertrophic cardiomyopathy: a literature review to inform economic model development

References

• Wasfy J, Walton S, Beinfeld M, et al. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; evidence report. Institute for Clinical and Economic Review; 2021.
   Google Scholar
• Cytokinetics. Data on file. South San Francisco, CA: Prevalence of Target Population; 2021.
   Google Scholar
• Maron MS, Hellawell JL, Lucove JC, et al. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016;117(10):1651–1654. doi: 10.1016/j.amjcard.2016.02.044.
   PubMed Web of Science ®Google Scholar
• Magnusson P, Palm A, Branden E, et al. Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes. Clin Epidemiol. 2017;9:403–410. doi: 10.2147/clep.S139300.
   PubMed Web of Science ®Google Scholar
• Husser D, Ueberham L, Jacob J, et al. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. PLoS One. 2018;13(5):e0196612. doi: 10.1371/journal.pone.0196612.
   PubMed Web of Science ®Google Scholar
• Butzner M, Maron M, Sarocco P, et al. Clinical diagnosis of hypertrophic cardiomyopathy over time in the United States (A Population-Based Claims Analysis). Am J Cardiol. 2021;159:107–112. doi: 10.1016/j.amjcard.2021.08.024.
   PubMed Web of Science ®Google Scholar
• Lu DY, Pozios I, Haileselassie B, et al. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2018;7(5):e006657. doi: 10.1161/jaha.117.006657.
   PubMed Web of Science ®Google Scholar
• Zytnick D, Heard D, Ahmad F, et al. Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: an interview study. Heart Lung. 2021;50(6):788–793. doi: 10.1016/j.hrtlng.2021.06.004.
   PubMed Web of Science ®Google Scholar
• Zaiser E, Sehnert AJ, Duenas A, et al. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102. doi: 10.1186/s41687-020-00269-8.
   PubMedGoogle Scholar
• Jain SS, Li SS, Xie J, et al. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2021;24(1):1115–1123. doi: 10.1080/13696998.2021.1978242.
   PubMed Web of Science ®Google Scholar
• Sharma S, Firoozi S, McKenna WJ. Value of Exercise Testing in Assessing Clinical State and Prognosis in Hypertrophic Cardiomyopathy. Cardiol Rev. 2001;9(2):70–76. doi: 10.1097/00045415-200103000-00005.
   PubMedGoogle Scholar
• Palandri C, Santini L, Argirò A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889–912. doi: 10.1007/s40265-022-01728-w.
   PubMed Web of Science ®Google Scholar
• Ciabatti M, Fumagalli C, Beltrami M, et al. Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2020;318:94–100. doi: 10.1016/j.ijcard.2020.07.036.
   PubMed Web of Science ®Google Scholar
• Minhas AMK, Wyand RA, Ariss RW, et al. Demographic and regional trends of hypertrophic cardiomyopathy-related mortality in the United States, 1999 to 2019. Circ Heart Fail. 2022;15(9):e009292. doi: 10.1161/circheartfailure.121.009292.
   PubMed Web of Science ®Google Scholar
• Psotka MA, Abraham WT, Fiuzat M, et al. Functional and symptomatic clinical trial endpoints: the HFC-ARC scientific expert panel. JACC Heart Fail. 2022;10(12):889–901. doi: 10.1016/j.jchf.2022.09.012.
   PubMed Web of Science ®Google Scholar
• Coats CJ, Maron MS, Abraham TP, et al. Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC Heart Fail. 2023;12(1):199–215. doi: 10.1016/j.jchf.2023.10.004.
   PubMed Web of Science ®Google Scholar
• Geske JB, Sorajja P, Ommen SR, et al. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol. 2009;32(7):397–402. doi: 10.1002/clc.20594.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769. doi: 10.1016/s0140-6736(20)31792-x.
   PubMed Web of Science ®Google Scholar
• Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023/01/03/. 2023;81(1):34–45. doi: 10.1016/j.jacc.2022.10.020.
   PubMed Web of Science ®Google Scholar
• CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM (SEQUOIA-HCM)
   Google Scholar
• Aficamten [Internet]. Cytokinetics. [cited 2024 Jun 19]. Available from: https://cytokinetics.com/aficamten/
   Google Scholar
• Cytokinetics. Cytokinetics announces positive results from SEQUOIA-HCM, the pivotal phase 3 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy. 2023. https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-positive-results-sequoia-hcm-pivotal
   Google Scholar
• You JJ, Woo A, Ko DT, et al. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154(5):899–907. doi: 10.1016/j.ahj.2007.06.026.
   PubMed Web of Science ®Google Scholar
• Takura T, Kyo S, Ono M, et al. Preliminary report on the cost effectiveness of ventricular assist devices. J Artif Organs. 2016;19(1):37–43. doi: 10.1007/s10047-015-0858-5.
   PubMed Web of Science ®Google Scholar
• Magnusson P, Wimo A. Health economic evaluation of implantable cardioverter defibrillators in hypertrophic cardiomyopathy in adults. Int J Cardiol. 2020;311:46–51. doi: 10.1016/j.ijcard.2020.02.055.
   PubMed Web of Science ®Google Scholar
• Haag MB, Hersh AR, Toffey DE, et al. Cost-effectiveness of in-home automated external defibrillators for children with cardiac conditions associated with risk of sudden cardiac death. Heart Rhythm. 2020;17(8):1328–1334. doi: 10.1016/j.hrthm.2020.03.018.
   PubMed Web of Science ®Google Scholar
• Haag MB, Hersh AR, Toffey DE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in children with cardiac conditions associated with risk for sudden cardiac death. Pediatr Cardiol. 2020;41(7):1484–1491. doi: 10.1007/s00246-020-02395-y.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Moss AJ, Maron BJ, et al. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10(4 Suppl):67–83. doi: 10.1111/j.1542-474X.2005.00070.x.
   PubMed Web of Science ®Google Scholar
• CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. CADTH; 2017.
   Google Scholar
• ICER’s. Reference Case for Economic Evaluations: principles and Rationale; 2020.
   Google Scholar
• NICE health technology evaluations: the manual. Process and methods. 2022.
   Google Scholar
• Ciani O, Grigore B, Blommestein H, et al. Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: a Retrospective Analysis across International Health Technology Assessment Agencies. Med Decis Making. 2021;41(4):439–452. doi: 10.1177/0272989x21994553.
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. York: Centre for Reviews and Dissemination, University of York; 2008.
   Google Scholar
• Rodrigues T, Raposo SC, Brito D, et al. Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review. Int J Cardiol. 2021;339:83–92. doi: 10.1016/j.ijcard.2021.06.051.
   PubMed Web of Science ®Google Scholar
• Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Heart Fail. 2015;8(6):1022–1031. doi: 10.1161/circheartfailure.114.002248.
   PubMed Web of Science ®Google Scholar
• Azarbal F, Singh M, Finocchiaro G, et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart. 2014;100(8):624–630. doi: 10.1136/heartjnl-2013-304908.
   PubMed Web of Science ®Google Scholar
• Masri A, Pierson LM, Smedira NG, et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J. 2015;169(5):684–692.e1. doi: 10.1016/j.ahj.2015.02.006.
   PubMed Web of Science ®Google Scholar
• Magri D, Agostoni P, Sinagra G, et al. Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2018;271:125–131. doi: 10.1016/j.ijcard.2018.04.019.
   PubMed Web of Science ®Google Scholar
• Moneghetti KJ, Stolfo D, Christle JW, et al. Value of Strain Imaging and Maximal Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(7):1203–1208. doi: 10.1016/j.amjcard.2017.06.070.
   PubMed Web of Science ®Google Scholar
• Sorajja P, Allison T, Hayes C, et al. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2012;109(10):1494–1498. doi: 10.1016/j.amjcard.2012.01.363.
   PubMed Web of Science ®Google Scholar
• Smith JR, Layrisse V, Medina-Inojosa JR, et al. Predictors of exercise capacity following septal myectomy in patients with hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2020;27(10):1066–1073. doi: 10.1177/2047487319898106.
   PubMed Web of Science ®Google Scholar
• Finocchiaro G, Haddad F, Knowles JW, et al. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail. 2015;3(5):408–418. doi: 10.1016/j.jchf.2014.11.011.
   PubMed Web of Science ®Google Scholar
• Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart. 2007;93(4):476–482. doi: 10.1136/hrt.2006.089656.
   PubMed Web of Science ®Google Scholar
• Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262–270. doi: 10.1067/mhl.2002.124554.
   PubMed Web of Science ®Google Scholar
• Single Technology Appraisal. Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531] Committee Papers. 2020.
   Google Scholar
• Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214. doi: 10.1080/13696998.2020.1824161.
   PubMed Web of Science ®Google Scholar
• Excellence NIfC. Guide to the methods of technology appraisal; 2008. http://www nice org uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal jsp
   Google Scholar